Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

75.0%

3 terminated/withdrawn out of 4 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

300%

3 of 1 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2
4(100.0%)
4Total
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02451423Phase 2Completed

Neoadjuvant Atezolizumab in Localized Bladder Cancer

Role: lead

NCT02506114Phase 2Terminated

Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer

Role: lead

NCT03007719Phase 2Terminated

Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1

Role: lead

NCT01530984Phase 2Withdrawn

Ipilimumab and GMCSF Immunotherapy for Prostate Cancer

Role: lead

All 4 trials loaded